| |
Values after 12 weeks
|
Change after 12 weeks
|
P Value (Difference Between add on vs. increased dose)
|
|---|
| |
Ezetimibe add-on group (n = 21)
|
Increased rosuvastatin (n = 18)
|
Ezetimibe add-on group (n = 21)
|
Increased rosuvastatin (n = 18)
|
|---|
|
ApoB, g/L
|
0.89 ± 0.25
|
0.88 ± 0.22
|
−0.17 ± 0.18*
|
−0.13 ± 0.25*
|
0.53
|
|
ApoA1, g/L
|
1.47 ± 0.26
|
1.56 ± 0.30
|
−0.07 ± 0.25
|
−0.05 ± 0.24
|
0.15
|
|
ApoB:ApoA1
|
0.55 ± 0.29
|
0.60 ± 0.23
|
−0.15 ± 0.29*
|
−0.12 ± 0.33
|
0.81
|
|
TC, mmol/L
|
4.23 ± 1.03
|
4.56 ± 0.75
|
−1.01 ± 0.79*
|
−0.50 ± 0.63*
|
0.03
|
|
LDL, mmol/L
|
2.12 ± 0.63
|
2.07 ± 0.46
|
−0.68 ± 0.54*
|
−0.48 ± 0.55*
|
0.37
|
|
HDL, mmol/L
|
1.21 ± 0.27
|
1.31 ± 0.48
|
−0.00 ± 0.29
|
0.03 ± 015
|
0.72
|
|
TC:HDL
|
3.29 ± 1.41
|
3.73 ± 0.92
|
−1.63 ± 2.86*
|
−0.52 ± 0.65*
|
0.09
|
|
TG, mmol/L
|
1.92 ± 0.98
|
2.88 ± 1.42
|
−0.62 ± 0.58*
|
−0.17 ± 0.57
|
0.03
|
|
AIP
|
0.16 ± 0.30
|
0.30 ± 0.38
|
−0.12 ± 0.20*
|
−0.03 ± 0.12
|
0.13
|
|
Non-HDL-C, mmol/L
|
3.06 ± 0.98
|
3.25 ± 0.71
|
−0.97 ± 0.68*
|
−0.53 ± 0.13
|
0.03
|
|
FBG, mmol/L
|
6.87 ± 2.49
|
5.82 ± 1.29
|
0.34 ± 1.28
|
−0.34 ± 1.75
|
0.15
|
|
hsCRP, mg/L
|
5.19 ± 7.25
|
1.72 ± 1.87
|
−0.60 ± 12.5
|
−1.06 ± 3.48
|
0.87
|
|
Creatinine, μmol/L
|
98 ± 58
|
151 ± 265
|
8 ± 48
|
53 ± 258
|
0.43
|
|
ALT, U/L
|
42 ± 22
|
34 ± 15
|
9 ± 17*
|
1.28 ± 16.6*
|
0.18
|
|
AST, U/L
|
32 ± 21
|
29 ± 8
|
4 ± 14
|
−0.10 ± 8
|
0.30
|
|
CK, U/L
|
126 ± 63
|
189 ± 103
|
−20 ± 90
|
12 ± 69
|
0.23
|
- Data are given as mean (±SD)
- *Significant change from their baseline (p < 0.05)
- apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides; API, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase
